Last reviewed · How we verify
dexmedetomidine with remifentanil
Dexmedetomidine with remifentanil, marketed by Yonsei University, is a combination therapy currently available in the market. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk is the lack of disclosed revenue data, which may limit investor confidence and strategic planning.
At a glance
| Generic name | dexmedetomidine with remifentanil |
|---|---|
| Sponsor | Yonsei University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery
- Awareness Neuraxial Versus General Anesthesia in Frail Patients Undergoing Laparoscopic or Robotic Abdominopelvic Surgery. (NA)
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Tubeless Strategy in Lung Transplantation: A Prospective Single-Arm Study (NA)
- Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery (NA)
- Dexmedetomidine and Myocardial Protection (NA)
- Tubeless Spontaneous Ventilation Anesthesia in Kidney Transplantation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dexmedetomidine with remifentanil CI brief — competitive landscape report
- dexmedetomidine with remifentanil updates RSS · CI watch RSS
- Yonsei University portfolio CI